Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack - THALES - Acute STroke or Transient IscHaemic Attack Treated with TicAgreLor and ASA for PrEvention of Stroke and Death

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack - THALES - Acute STroke or Transient IscHaemic Attack Treated with TicAgreLor and ASA for PrEvention of Stroke and Death

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2019

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms THALES
  • Sponsors AstraZeneca
  • Most Recent Events

    • 02 Mar 2018 Planned End Date changed from 5 Dec 2019 to 16 Dec 2019.
    • 02 Mar 2018 Planned primary completion date changed from 5 Dec 2019 to 16 Dec 2019.
    • 02 Feb 2018 Planned End Date changed from 16 Dec 2019 to 5 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top